Instrument Inactif

Communiqués Big Cypress Acquisition Corp. Nasdaq

Actions

BCYPU

US0891152086

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

UNAUDITED PRO FORMA COMBINED CONDENSED CONSOLIDATED FINANCIAL INFORMATION - Form 8-K	28/10/21	PU
BIG CYPRESS ACQUISITION CORP. : Submission of Matters to a Vote of Security Holders (form 8-K)	21/10/21	AQ
Big Cypress Acquisition Corp. : Stockholders Approve Business Combination with SAB Biotherapeutics	21/10/21	PR
SAB Corporate Presentation	15/10/21	PU
BIG CYPRESS ACQUISITION CORP. : Other Events (form 8-K)	13/10/21	AQ
R&D Day Presentation	13/10/21	PU
BIG CYPRESS ACQUISITION CORP. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	12/10/21	AQ
Big Cypress Acquisition : SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021	06/10/21	BU
Big Cypress Acquisition : SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19	04/10/21	BU
SAB Biotherapeutics : Appoints Russell Beyer Chief Financial Officer	28/09/21	BU
SAB Biotherapeutics : annonce que le SAB-185 a reçu une très bonne évaluation d'un comité de contrôle des données (CICD) et qu'il progresse désormais vers la Phase 3 dans le cadre de l'essai ACTIV-2 sponsorisé par les National Institutes of Health...	25/09/21	BU
SAB Biotherapeutics : Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19	24/09/21	BU
Big Cypress Acquisition Corp : Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics	23/09/21	PR
Big Cypress Acquisition : SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19	22/09/21	BU
SAB Biotherapeutics : Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza	15/09/21	BU
SAB Biotherapeutics : to Present at Upcoming September Virtual Investor Conferences	08/09/21	BU
Big Cypress Acquisition : FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER (Form 8-K)	16/08/21	PU
BIG CYPRESS ACQUISITION CORP. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	16/08/21	AQ
Big Cypress Acquisition : SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants	11/08/21	BU
BIG CYPRESS ACQUISITION : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	09/08/21	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Big Cypress Acquisition Corp. Nasdaq

Actions

BCYPU

US0891152086

Communiqués

Filtres